Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Janssen
Woman and Man Max 99 years
Yvonne JM Janssen-Potten, PhD
Update Il y a 4 ans
Upper Extremity Strength in Cerebral Palsy
Rationale: Children with Cerebral Palsy (CP) experience limitations in motor activities and participation in the community, predominantly caused by impairments in muscle function. A...
Country
None
organs
None
Specialty
None
Opened trial
More information
Woman and Man
Between 18 years
and 99 years
Janssen
Update Il y a 4 ans
A First-in-Human Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of JNJ-74699157 in Participants with Advanced Solid Tumors Harboring the KRAS G12C Mutation
A First-in-Human Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of JNJ-74699157 in Participants with Advanced Solid Tumors Harboring the KRAS G12C Mutation
Country
France
organs
Poumon, type non à petites cellules
,
Côlon ou Rectum (colorectal)
Specialty
Thérapies Ciblées
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
A double-blind, placebo-controlled Clinical Trial to evaluate the Safety and Efficacy of JNJ-64304500 in patients with Moderately to Severely Active Crohn’s Disease
- To evaluate the efficacy of JNJ-64304500 to reduce the CDAI score from baseline. - To evaluate the safety of JNJ-64304500.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
Update Il y a 4 ans
A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects with Schizophrenia
The primary objective of this study is to demonstrate that paliperidone palmitate is not less effective than risperidone LAI. The safety and tolerability of paliperidone palmitate in the treatment of ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
A Randomized, Double-Blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Efficacy of JNJ 40929837 for the Treatment of Asthma Using a Bronchial Allergen Challenge Model
To evaluate the allergen-induced late asthmatic response (LAR), as measured by maximal percent fall in FEV1, in subjects with stable mild atopic asthma after treatment with JNJ 40929837 compared to pl...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
An Efficacy And Safety of CNTO 6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The change from baseline in pre-bronchodilator FEV1 at Week 16
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
A Randomized, Open-Label, Multicenter Study of VELCADE with Rituximab or Rituximab Alone in Subjects with Relapsed or Refractory, Rituximab Naive or Sensitive Follicular B-cell Non Hodgkin's Lymphoma
The primary objective of this study is to determine whether VELCADE with rituximab provides benefit to subjects with relapsed or refractory, rituximab naive or sensitive follicular B-NHL relative to t...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen R&D Ireland
Update Il y a 4 ans
TMC435-TiDP16-C208 - Phase III Trial of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients
To demonstrate the superiority of TMC435 versus placebo as part of a treatment regimen including peginterferon alfa-2a (PegIFNα-2a) and ribavirin (RBV), with respect to the proportion of subjects with...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
A study to evaluate the dose response of JNJ-54781532 in participants with moderately to severely active ulcerative colitis (UC)
1. To evaluate the dose response of JNJ-54781532 at Week 8 in subjects with moderately to severely active UC. 2. To evaluate the safety of JNJ-54781532 in subjects with moderately to severely active ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen Biologics B.V
Update Il y a 4 ans
A Multicenter Trial Comparing REMICADE (infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
The primary objective of this study will be to compare the efficacy of infliximab with that of placebo in the prevention of clinical recurrence of CD through Week 76, defined as a composite endpoint t...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next